Sen. Hatch, Biopharma Industry Champion, Ready To Hang Up His Gloves
Executive Summary
Hatch had a hand in major bipartisan legislation creating markets for generic drugs, orphan drugs, biosimilars, and dietary supplements.
You may also be interested in...
Democrat-Controlled House Will Turn Up The Volume On Drug Pricing
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will likely need to dovetail with President Trump’s agenda to advance.
Democrat-Controlled House Will Turn Up The Volume On Drug Pricing
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.
'Big Shoes To Fill' As Hatch Retirement Leaves Supplement Market Legacy
Sen. Orrin Hatch won’t seek re-election and will leave 24 years after Congress passed the Dietary Supplement Health and Education Act as a framework for FDA's regulation of vitamin, mineral and supplement product manufacturing and marketing. Hatch is in his seventh term and is the longest-serving Senate member.